TIDMONC
RNS Number : 6297B
Oncimmune Holdings PLC
24 September 2018
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014. Upon the publication of
this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Board Change
Adam Hill Appointed as CEO and Geoffrey Hamilton-Fairley
Transitions to Vice Chairman
New Management Structure to Deliver Existing Strategy and
Additional Opportunities from Technology Platform
Nottingham, UK - 24 September 2018: Oncimmune Holdings plc (AIM:
ONC.L), a leader in the development, manufacture and marketing of
personalised immunodiagnostics for the screening, detection and
care of cancer, has appointed Adam Hill as Chief Executive Officer.
His appointment follows founder Geoffrey Hamilton-Fairley's
decision to step down as Chief Executive Officer and into a new
role as Vice Chairman of the Company's Board of Directors and is
effective 1(st) October 2018.
Dr Hill joined Oncimmune as Chief Medical Officer and Chief
Scientific Officer and Executive Director earlier this year from
McLaren Applied Technologies, where he was Chief Strategy Officer
and responsible for its portfolio of health programmes,
co-developed in partnership with blue chip pharma and medical
device companies. Adam is a clinician-scientist, with a career
built in industry, academia and care delivery. During his career,
Adam has been responsible for developing technology and commercial
strategies in the medical device and diagnostics industry, and has
held senior leadership roles at private and listed companies,
supplemented by advisory and government policy appointments.
Since joining Oncimmune, Dr Hill has been leading both the
R&D team and a strategic review of the Company, with a view to
identifying and capitalising on the opportunities presented by
Oncimmune's proprietary auto-antibody-based platform for individual
profiling of cancer related antigens. This strategic review has
confirmed the promise of the platform for individual profiling,
early detection, improved care and new insights into the
application of personalised approaches to improving cancer outcomes
through new therapeutics. Further detail on plans to execute
expansion through the roll out of additional EarlyCDT(R) tests and
application of the platform in other areas of the cancer clinical
pathway will be presented at the time of the Company's results for
the year ended 31 May 2018, which are expected in October.
Mr Hamilton-Fairley, an early pioneer in the field of cancer
immunodiagnostics, joined Oncimmune in 2005 as it was established
as a spin out of Nottingham University, and led the Company's
transition to a commercial phase company with the launch in the US
of two early detection blood based tests in lung and liver cancer.
He also led the geographic expansion with important collaborative
partnerships in China, Europe and the Middle East.
Mr Hamilton-Fairley will transition to a new created role of
Vice Chairman of the Board of Directors and assist in developing
the new senior leadership team as well as continuing to support the
Company on certain key strategic projects.
Meinhard Schmidt, Non-Executive Chairman of Oncimmune,
commented: "We would like to thank Geoffrey for his vision and
commitment over the last 13 years, which has led to Oncimmune
becoming a leader in immunodiagnostics for cancer. He has built an
experienced international team, strong internal science and a
development platform with the capability to attract research
partnerships and to establish next generation technology with new
collaborations worldwide as the portfolio of programmes and
products expands beyond the lung and liver tests to maximise
shareholder value.
"We are delighted to welcome Adam as Oncimmune's new CEO. His
experience in the science, medicine and technology of personalised
approaches to diagnostics and optimisation of healthcare delivery
are an excellent fit for the Company's ambitions as we progress
towards realising our goals of delivering early detection and
improved care for cancer patients."
Geoffrey Hamilton-Fairley commented: "It has been a great
experience leading Oncimmune from its spin out from Nottingham
University and a team of dedicated colleagues and research
collaborators who have been working together to transform the
treatment of cancer through immunodiagnostics leading to early
detection and improved care and outcomes. The Company is well
positioned for an exciting future and it is now time to transition
to new leadership who will take our products and technology through
clinical development and broad global commercialisation, and Adam
has demonstrated that he is the ideal leader to deliver the next
phase of Oncimmune's growth. My thanks and appreciation to the
extended Oncimmune team and partners, past and present."
Adam Hill commented: "Oncimmune has a strong and proprietary
position in immune profiling of cancer, and a compelling pipeline
of clinical and commercial phase assets that will help unlock the
potential of personalised immunodiagnostics for a broad portfolio
of cancer indications. As the field of oncology sits on the cusp of
dramatically improved cancer survivorship, I look forward to
working with the Company's experienced Board, and its highly
talented executive and scientific teams to take Oncimmune's
immunodiagnostic solutions through clinical development and into
the hands of clinicians to improve patient outcomes."
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Geoffrey Hamilton-Fairley, Vice Chairman
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Ben Burnett
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Alix Mecklenburg-Solodkoff
+44 (0)20 3207 7800
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
About Oncimmune
Oncimmune is a leader in the development, manufacture and
marketing of personalised immunodiagnostics for the screening,
detection and care of cancer. The Group has pioneered the
development of autoantibody tests that can detect cancer up to four
years earlier than other methods and can be applied to a very wide
range of solid tumour types. The Company's first product,
EarlyCDT(R)-Lung, was launched in 2012, as a CLIA test in the USA
and since then over 155,000 commercial tests have been sold.
EarlyCDT(R)-Lung is available through physicians in the US and also
privately in the UK, Europe & Asia. EarlyCDT(R)-Lung is being
used in the largest ever randomised trial for the early detection
of lung cancer using biomarkers, the National Health Service (NHS)
Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT(R)-Liver
launched in May 2018 and further tests are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASEAFIDFASEDU
(END) Dow Jones Newswires
September 24, 2018 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024